Gilead Sciences, Inc. Live Stock Price Today, Share Analysis and Chart

Name: Gilead Sciences, Inc.: Is Infosys Ltd. worth buying?
Item: Gilead Sciences, Inc.
Rating: 2.593458375
Author: Trendlyne DVM scores

Mid-range Performer

about

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

112.97 0.41 (0.36%)

45.32% Gain from 52W Low

4.6M

XNAS Volume

XNAS 29 Aug, 2025 5:30 PM (EDT)

Dividend

Gilead Sciences, Inc. has an upcoming dividend of $0.79 per share due on 15 Sep 2025 See details

Medium Financial Strength

50.0 / 100

Mid Valuation

48.8 / 100

Technically Neutral

58.8 / 100

Mid-range Performer These stocks average quality, financial and technical aspects make them being considered by the investor who are not looking for high risk stocks. View Similar Embed DVM

124

1Yr Price target upside is 10%

25 analysts

Gilead Sciences Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Gilead Sciences, Inc. Live Stock Price Today, Share Analysis and Chart

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Soval...

45.32% Gain from 52W Low

SWOT Analysis

Gilead Sciences Live Price Chart